🧬 Unlocking RNA Targets: Advancing Drug Discovery with Cutting-Edge Simulations 💫
At Qubit Pharmaceuticals, we’ve made a breakthrough in computational drug design, tackling one of the biggest challenges in modern medicine: RNA-targeted therapeutics.
By combining cutting-edge technologies like:
🔸 Lambda-ABF for precision binding affinity prediction
🔸 Tinker-HP for enhanced molecular dynamics
🔸 Advanced sampling techniques in combination with machine learning to capture complex RNA conformational changes
…we're paving the way for faster, more accurate drug discovery, with unprecedented insights into RNA-small molecule interactions. RNA-targeting therapeutics also expand the druggable target space in the human genome from 0.2% to ~70%, offering an attractive alternative to reach traditionally undruggable proteins!
📰Our latest blog explores how our advanced methods open new possibilities for designing drugs to treat the most difficult diseases. The blog is based on a scientific publication, currently available as a preprint, showcasing these innovations.
A special thanks to our partners Bpifrance, European Innovation Council and SMEs Executive Agency (EISMEA) , #FRANCE 2030, GENCI , Secrétariat général pour l'investissement, Région Île-de-France, and Sorbonne Université, as well as our investors Quantonation, XAnge & Omnes.
And, of course, 👏massive congratulations👏 to the authors, Narjes A. , Chengwen Liu, Florent Hédin, Jérôme Hénin, Jay Ponder, Pengyu Ren, Jean-Philip Piquemal, Louis Lagardère, and Krystel El Hage, PhD El Hage for their remarkable work!
👉 Read more and discover how we're revolutionizing RNA drug discovery: https://loom.ly/SdIjUxA
👉 Straight to the preprint? Sure! https://loom.ly/Al9PcUU
Pharmaceuticals and biotech companies seeking to unlock new treatment possibilities, let’s collaborate and make the next breakthrough together - Reach out to us today!
#ComputationalChemistry #QuantumAidedDrugDesign #RNAtherapeutics #DrugDiscovery